Ultragenyx Pharma (RARE) Misses Q3 EPS by 16c

Ultragenyx Pharma (NASDAQ: RARE) reported Q3 EPS of ($2.23), $0.16 worse than the analyst estimate of ($2.07). Revenue for the quarter came in at $98.1 million versus the consensus estimate of $109.79 million.

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.

You May Also Be Interested In

• After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
• Evercore ISI Downgrades Ultragenyx Pharma (RARE) to In Line
• Five Below raises full-year outlook after strong second-quarter sales growth